JP2024538117A5 - - Google Patents

Info

Publication number
JP2024538117A5
JP2024538117A5 JP2024522406A JP2024522406A JP2024538117A5 JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5 JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5
Authority
JP
Japan
Application number
JP2024522406A
Other languages
Japanese (ja)
Other versions
JP2024538117A (ja
JPWO2023064282A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046291 external-priority patent/WO2023064282A1/en
Publication of JP2024538117A publication Critical patent/JP2024538117A/ja
Publication of JPWO2023064282A5 publication Critical patent/JPWO2023064282A5/ja
Publication of JP2024538117A5 publication Critical patent/JP2024538117A5/ja
Pending legal-status Critical Current

Links

JP2024522406A 2021-10-13 2022-10-11 Wee1阻害剤と抗cd47抗体との組み合わせ。 Pending JP2024538117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163262466P 2021-10-13 2021-10-13
US63/262,466 2021-10-13
PCT/US2022/046291 WO2023064282A1 (en) 2021-10-13 2022-10-11 Combinations of wee 1 inhibitors and anti-cd47 antibodies.

Publications (3)

Publication Number Publication Date
JP2024538117A JP2024538117A (ja) 2024-10-18
JPWO2023064282A5 JPWO2023064282A5 (https=) 2025-10-22
JP2024538117A5 true JP2024538117A5 (https=) 2025-10-22

Family

ID=85987727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522406A Pending JP2024538117A (ja) 2021-10-13 2022-10-11 Wee1阻害剤と抗cd47抗体との組み合わせ。

Country Status (6)

Country Link
US (1) US20240261295A1 (https=)
EP (1) EP4415721A4 (https=)
JP (1) JP2024538117A (https=)
CN (1) CN118139625A (https=)
TW (1) TW202320758A (https=)
WO (1) WO2023064282A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
BR112023000350A2 (pt) 2020-07-09 2023-03-28 Recurium Ip Holdings Llc Sais e formas de um inibidor de wee1
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
US20220184087A1 (en) * 2019-03-28 2022-06-16 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
CN114555123B (zh) * 2019-10-18 2024-04-02 四十七公司 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法

Similar Documents

Publication Publication Date Title
JP2024539872A5 (https=)
JP2024538117A5 (https=)
BR102022025291A2 (https=)
BR102022023461A2 (https=)
BY13158U (https=)
BY13151U (https=)
CN307049323S (https=)
CN307048422S (https=)
CN307048360S (https=)
CN307047571S (https=)
CN307047423S (https=)
BY13156U (https=)
CN307046382S (https=)
CN307046337S (https=)
CN307046025S (https=)
CN307045825S (https=)
CN307044649S (https=)
CN307044363S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
BY13169U (https=)